Mikael Dolsten

Dr. Mikael Dolsten is a physician-scientist, biotechnology leader, and corporate director whose career has spanned more than 35 years at the forefront of biomedical innovation and global healthcare. He spent more than 16 years at Pfizer, most recently as Chief Scientific Officer and President of Worldwide Research, Development and Medical. In that role, he led one of the world’s largest pharmaceutical R&D organizations and contributed to the development and approval of approximately 40 medicines and vaccines. Dr. Dolsten played a key leadership role in the development of the COVID-19 vaccine Comirnaty and the antiviral medicine Paxlovid, helping advance the global response to the pandemic.

Today, he serves on the boards of public and private life-science and technology companies and advises leading investment and innovation organizations focused on advancing biomedical research and healthcare. He is actively involved in supporting the next generation of biotechnology and AI-enabled companies developing transformative approaches to medicine.

Dr. Dolsten has authored more than 160 scientific publications and is an elected member of the Royal Swedish Academy of Engineering Sciences. He has advised governments and international organizations on public health, biomedical innovation, and pandemic preparedness. Prior to Pfizer, he held senior scientific and executive leadership positions at Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, and Pharmacia.